London (UK) and Rehovot (Israel) April 26, 2023
Vidac Pharma Holding Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). (www.vidacpharma.com)
In preparation for its new status as a public company registered in the Hamburg stock Exchange (T9G, WKN: A3DTUQ, ISIN:GB00BM9XQ619), Vidac Pharma Holding (The Company) is expanding its company board: Mr. Joseph Tenne, CPA, a financial expert and Dr. Christian Policard, Ex- Executive vice President of Sanofi and previous director of Pasteur Institute, will join the Company Board as per May, 15th, 2023
Both are Board members of the Company subsidiary Vidac Pharma ltd., Rehovot, Israel. Prof. Michael Rossbach from Munich, Germany, an immunology and cell-based therapy expert as well as Prof. Kristian Reich from Hamburg, Germany, a dermatology and translational research expert will join the Scientific Advisory Committee headed by Dr. Oren Becker, Previous CEO of Vidac Pharma Ltd. and a bioinformatic expert.
About Vidac Pharma: Vidac Pharma Holding Plc. London, is the holding company of Vidac Pharma Ltd. Rehovot. The Company is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases.
The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.
Vidac Pharma Holding PLC